UY30535A1 - Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. - Google Patents
Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.Info
- Publication number
- UY30535A1 UY30535A1 UY30535A UY30535A UY30535A1 UY 30535 A1 UY30535 A1 UY 30535A1 UY 30535 A UY30535 A UY 30535A UY 30535 A UY30535 A UY 30535A UY 30535 A1 UY30535 A1 UY 30535A1
- Authority
- UY
- Uruguay
- Prior art keywords
- antirretroviral
- pharmacos
- applications
- preparation process
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920000642 polymer Polymers 0.000 title abstract 2
- 229940125366 antir retro viral Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 229960004525 lopinavir Drugs 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invencion proporciona: - Composicion oral solida comprendiendo uno o más fármacos antirretrovirales, por ejemplo, inhibidores de proteasa como el lopinavir, ritonavir o una combinacion de estos con uno o más excipientes, o con al menos un polímero insoluble en agua, en donde 1 a relacion de fármaco a polímero en la composicion está en el intervalo de aproximadamente 1: 1 hasta alredodor de 1:6, - Composicion que es más pequena para la cantidad correspondiente del principio activo, que además posee propiedad de enmascaramiento del sabor - Proceso para la elaboracion de las composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1269MU2006 | 2006-08-10 | ||
IN1227MU2007 | 2007-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30535A1 true UY30535A1 (es) | 2008-03-31 |
Family
ID=38667164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30535A UY30535A1 (es) | 2006-08-10 | 2007-08-10 | Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100173921A1 (es) |
AU (1) | AU2007283196A1 (es) |
BR (1) | BRPI0714265A2 (es) |
CA (1) | CA2660374A1 (es) |
CL (1) | CL2007002331A1 (es) |
PE (1) | PE20080422A1 (es) |
TW (1) | TW200815033A (es) |
UY (1) | UY30535A1 (es) |
WO (1) | WO2008017867A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037398A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
PL2487161T3 (pl) | 2007-02-23 | 2017-03-31 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
SG190618A1 (en) | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
WO2009153654A1 (en) * | 2008-06-17 | 2009-12-23 | Aurobindo Pharma Limited | Solid dosage forms of antiretrovirals |
HUE030800T2 (en) * | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
US20130142877A1 (en) | 2010-05-10 | 2013-06-06 | Evonik Roehm Gmbh | Pharmaceutical dosage form comprising one or more antiretroviral active ingredients |
MY171941A (en) | 2010-11-24 | 2019-11-08 | Melinta Subsidiary Corp | Pharmaceutical compositions |
GB201118182D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2013131646A1 (en) * | 2012-03-07 | 2013-09-12 | Ratiopharm Gmbh | Dosage form comprising lopinavir and ritonavir |
MX2014013326A (es) | 2012-05-03 | 2015-08-10 | Cipla Ltd | Composición antirretroviral. |
TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
WO2014080365A1 (en) * | 2012-11-23 | 2014-05-30 | Ranbaxy Laboratories Limited | Method of reducing an unpleasant odor of a pharmaceutical composition |
RU2505286C1 (ru) * | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
CN103550993B (zh) * | 2013-10-30 | 2015-07-08 | 王维玲 | 一种大气污染洁净剂及制备方法、洁净剂的应用及应用方法 |
PL3250182T3 (pl) * | 2015-01-27 | 2023-07-31 | Janssen Pharmaceutica Nv | Kompozycje dyspergowalne |
RU2744270C2 (ru) * | 2015-12-28 | 2021-03-04 | ЭсЭсПи КО., ЛТД., ДЖАПАН | Прессованный фармацевтический препарат |
GB2625584A (en) * | 2022-12-21 | 2024-06-26 | Rb Health Us Llc | Novel composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
MXPA03009971A (es) * | 2001-05-03 | 2004-02-12 | Hoffmann La Roche | FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO. |
DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
BRPI0707465B8 (pt) * | 2006-02-03 | 2022-07-05 | Evonik Roehm Gmbh | composições farmacêuticas compreendendo misturas de polímeros e ingredientes ativos dificilmente solúveis em água, seu uso e seus processos de preparação, forma farmacêutica e seu processo de produção |
-
2007
- 2007-08-10 AU AU2007283196A patent/AU2007283196A1/en not_active Abandoned
- 2007-08-10 BR BRPI0714265-0A patent/BRPI0714265A2/pt not_active IP Right Cessation
- 2007-08-10 CL CL200702331A patent/CL2007002331A1/es unknown
- 2007-08-10 CA CA002660374A patent/CA2660374A1/en not_active Abandoned
- 2007-08-10 US US12/377,038 patent/US20100173921A1/en not_active Abandoned
- 2007-08-10 WO PCT/GB2007/003061 patent/WO2008017867A2/en active Application Filing
- 2007-08-10 TW TW096129786A patent/TW200815033A/zh unknown
- 2007-08-10 PE PE2007001072A patent/PE20080422A1/es not_active Application Discontinuation
- 2007-08-10 UY UY30535A patent/UY30535A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20100173921A1 (en) | 2010-07-08 |
TW200815033A (en) | 2008-04-01 |
BRPI0714265A2 (pt) | 2013-04-16 |
PE20080422A1 (es) | 2008-04-28 |
CL2007002331A1 (es) | 2008-04-18 |
CA2660374A1 (en) | 2008-02-14 |
WO2008017867A3 (en) | 2009-04-16 |
WO2008017867A2 (en) | 2008-02-14 |
AU2007283196A1 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30535A1 (es) | Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. | |
CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
GT200700034A (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40 | |
AR105712A1 (es) | Composiciones de insulina de rápida acción | |
HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
CR11285A (es) | Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
BR112016026667A8 (pt) | comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v | |
CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
CO6300935A2 (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
CL2022002531A1 (es) | Moduladores de nlrp3 | |
AR075041A1 (es) | Composicion farmaceutica que contiene aleglitazar, proceso, uso. | |
AR070392A1 (es) | Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion | |
AR062925A1 (es) | Metodo para fabricar tabletas que contienen agentes farmacologicamente activos | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
MX2022001802A (es) | Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre. | |
ECSP22092205A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
BRPI1010987B8 (pt) | composições de dosagem sólida de liberação controlada contendo ibuprofeno | |
UY39503A (es) | Formulación sólida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20190815 |